What's Happening?
Daewoong Therapeutics has announced that its semaglutide microneedle patch achieved over 80% relative bioavailability compared to injectable formulations in a pilot human pharmacokinetic study. This breakthrough was achieved using Daewoong's CLOPAM® drug-delivery platform, which enhances delivery efficiency. The study involved 70 healthy adults receiving either the microneedle patch or a subcutaneous injection, with plasma concentrations measured for comparison. The patch demonstrated significantly higher bioavailability than existing microneedle patches and oral tablets, maintaining therapeutic plasma levels for one week, suggesting potential for once-weekly dosing.
AD
Why It's Important?
This development represents a significant advancement in drug delivery technology, particularly in the obesity treatment market. The high bioavailability of the microneedle patch addresses key limitations of current therapies, such as injection pain and low oral formulation efficiency. This innovation could lead to improved patient adherence and convenience, potentially positioning Daewoong Therapeutics as a leader in the global obesity therapeutics market. The technology also aligns with sustainability goals by reducing medical waste and distribution costs.
What's Next?
Daewoong Therapeutics plans to expand its microneedle technology globally through licensing and co-development initiatives. The company aims to broaden its collaborative efforts to prepare for commercialization, potentially impacting the global obesity treatment market. Stakeholders, including pharmaceutical companies and healthcare providers, may explore partnerships with Daewoong to leverage this innovative technology.
